SAN ANTONIO, TX, JULY 15, 2009 11:00 A.M. (CST). America Stem Cell, Inc. (ASC) www.americastemcell.com announced today that the company has been awarded $2.5 million from the State of Texas Emerging Technology Fund (“ETF”) www.emergingtechfund.com. This investment will enable ASC to accelerate the development of its breakthrough enzyme technology to enhance the homing and engraftment of cord blood stem cells, and achieve improved clinical outcomes for cancer patients receiving these stem cell transplants. ASC’s enzyme treatment could potentially transform cord blood stem cell engraftment, accelerate patients’ immune system and platelet recovery, reduce opportunistic infections and improve cord blood stem cell
Stem Cell Enabling Technologies Unveiled at Cord Blood Transplantation Meeting in LA
Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow
Xia L, McDaniel JM, Yago T, Doeden A, McEver RP. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood. 2004 Nov 15;104(10):3091-6. Epub 2004 Jul 27.